GYNECOMASTIA--TREATMENT WITH DIHYDROTESTOSTERONE HEPTANOATE

男性乳房发育症——庚酸二氢睾酮治疗

• 批准号: 3763251
• 负责人: BRUCE S. KEENAN
• 金额: --
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3763251
• 关键词: dihydrotestosterone; endocrine pharmacology; gynecomastia; hormone therapy; human subject; human therapy evaluation; insulin; insulinlike growth factor; male; obesity; reproductive system disorder chemotherapy; somatotropin

Uses a comparison of obese and lean subjects with GCM to gain further insight into the mechanisms controlling the growth of fibroglandular tissue in the male and the most appropriate methods of treatment. Hypotheses are that DHT treatment will result in regression of the fibroglandular tissue, will have an equal effect in the two groups, and the development of gynecomastia in lean and obese individuals is independent of differences in circulating levels of GH, IGF1 and insulin.

使用GCM比较肥胖和瘦受试者，以进一步获得 深入了解控制纤维腺生长的机制 组织在男性和最适当的治疗方法。 假设双氢睾酮治疗将导致 纤维腺体组织，将在两组中具有相同的效果，并且 男性乳房发育症在瘦型和肥胖型个体中的发展是 独立于GH、IGF1和胰岛素循环水平的差异。